Duplicα RealTime ApoE Genotyping Kit

In vitro diagnostic kit based on real-time PCR for the qualitative detection of the ApoE*E2, ApoE*E3 and ApoE*E4 alleles in human genomic DNA.

Detailed Description

Operating principle

The kit is based on the specific amplification of target sequences by Real-Time PCR, using specific fluorescent probes.

Allelic discrimination is performed using labelled probes:

FAM (6-carboxyfluorescein) to detect cysteine (Cys) HEX (hexachlorofluorescein) to detect arginine (Arg)

The fluorescent signal emitted during amplification makes it possible to identify the amino acid substitutions corresponding to the ApoE*E2, E3 and E4 alleles.

Clinical applications

Genotyping of the ApoE gene in human samples. Assessment of the genetic risk associated with Alzheimer’s disease (AD). Support for studies on lipid metabolism and neurodegenerative diseases. Potential utility in predicting response to treatments (e.g. response to anticholinesterase drugs according to ApoE genotype).

Results or key indicators

Qualitative identification of the alleles:

ApoE*E2 (Cys112-Cys158) ApoE*E3 (Cys112-Arg158) ApoE*E4 (Arg112-Arg158)

Genotype determination:

Homozygous: E2/E2, E3/E3, E4/E4 Heterozygous: E2/E3, E2/E4, E3/E4

Technology used

Real-time PCR (Real-Time PCR) Specific fluorogenic probes (TaqMan®-type technology) Multichannel detection (FAM / HEX) Compatible with multiple platforms:
Rotor-Gene® Q (Qiagen) CFX96 / Opus (Bio-Rad) Applied Biosystems® 7500 ELITe InGenius® and ELITe BeGenius®

Key Aspects

Specific detection of the ApoE E2, E3 and E4 alleles.
Technology based on Real-Time PCR with fluorescent probes.
High specificity through allelic discrimination (FAM/HEX).
Compatible with multiple real-time PCR platforms.
Includes positive controls (wild type and mutant) and a negative control.
Applicable to Alzheimer’s disease risk studies.
Ready-to-use format.
Presentation Details

Kit format: 32 tests (ref. EER018032)

Contents:

Amplification mixes (aa112 and aa158) Oligonucleotide mixes (aa112 and aa158) Control 1 (Cys, wild type) Control 2 (Arg, mutant) Reaction blank (BM)

Configuration:

Two separate boxes (aa112 and aa158) Reaction volume: 25 µl Required DNA: 100–250 ng per reaction

Capacity:

Up to 32 determinations Validated for use in multiple sessions

Storage conditions:

-22°C to -18°C Maximum of 6 freeze/thaw cycles

Sample type: Peripheral blood in EDTA

Area:

Hereditary and/or Rare Diseases, Molecular Genetics

Brand:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

SureSelect Cancer CGP Assay

Targeted-enrichment NGS pan-cancer panel for comprehensive genomic profiling (CGP) of solid tumours. Designed to detect somatic variants at DNA level (SNVs, indels, CNVs, translocations) and RNA level (gene fusions), as well as to assess complex immuno-oncology biomarkers such as tumour mutational burden (TMB), microsatellite instability (MSI) and homologous recombination deficiency (HRD). Detailed Description Operating principle…
Agilent
Next Generation Sequencing (NGS)

SeqOne HRD Solution con Agilent SureSelect CD HRR17 Panel

HRD analysis solution combining low-coverage whole-genome sequencing (shallow/low-pass WGS) and a targeted gene panel to detect genomic instability, BRCA1/2 alterations and other genes related to homologous recombination. It is designed for laboratories wishing to implement HRD testing in-house with an automated, efficient and clinically validated workflow. Detailed Description SeqOne’s HRD solution combines shallow WGS and…
Agilent
Next Generation Sequencing (NGS)

OncoSELECT®

Comprehensive targeted liquid biopsy assay designed to support decision-making in oncology through the analysis of 74 clinically relevant genes. The solution encompasses everything from library preparation reagents to bioinformatics analysis, clinical interpretation and the generation of detailed reports. 3.- Detailed Description Operating principle OncoSELECT® is an advanced liquid biopsy panel based on circulating cell-free DNA…
OncoDNA
Next Generation Sequencing (NGS)

Agilent SureSelect Human All Exon V8.

High-performance exome for the enrichment of human coding regions, with updated coverage of RefSeq, CCDS and GENCODE, including the TERT promoter and difficult-to-capture exons. 3.- Detailed Description Operating principle SureSelect Human All Exon V8 is based on NGS library preparation and capture enrichment of target regions of the human exome. The workflow is compatible with…
Agilent
Next Generation Sequencing (NGS)